A Phase 1B/2 Study Of Tergenpumatucel-L (Hyperacute Lung) Immunotherapy In Combination With The Ido Pathway Inhibitor Indoximod And Docetaxel In Pati
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
In this clinical study we will look at the safety and anti-tumor effects of the combination of the experimental drugs tergenpumatucel-L immunotherapy and indoximod with the approved drug therapy docetaxel. ?Experimental? means the drug has not been approved by any Authority that regulates new medic
Criteria:
To Be Eligible To Participate, Patients Must Have Been Diagnosed With Cancer Of The Lung.
Keywords:
Cancer, Lung, Nlg-0401, Non Small Cell, Previously Treated
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu